Aligos Therapeutics, Inc. (ALGS)

0.8010 +0.0510 (+6.80%) At close: 04:00PM EDT

Aligos Therapeutics, Inc.

One Corporate Drive
2nd Floor
South San Francisco, CA 94080
United States
800 466 6059
https://www.aligos.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 66

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Lawrence M. Blatt MBA, Ph.D.	CEO, President & Chairman of the Board	832.73k	N/A	1962
Dr. Julian A. Symons DPHIL	Executive VP & Chief Scientific Officer	618.66k	N/A	1962
Ms. Lesley Ann Calhoun CPA	Executive VP & CFO	N/A	N/A	1966
Kristina Engeseth	VP and Head of People & Culture	N/A	N/A	N/A
Dr. Matthew W. McClure M.D.	Executive VP & Chief Medical Officer	N/A	N/A	1972
Dr. Sushmita M. Chanda DABT, Ph.D.	Executive Vice President & Chief Development Officer	N/A	N/A	1967
Dr. David B. Smith Ph.D.	Executive VP & Head of Chemical Operations	N/A	N/A	N/A
Dr. Tse-I Lin Ph.D.	VP of Early Compound Development & Belgian Site Head	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Corporate Governance

Aligos Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.